John Y Wong

US Patent:

6361979, Mar 26, 2002

Filed:

Jan 27, 2000

Appl. No.:

09/492548

Inventors:

Michael P. Burns - Mystic CT
James J. Cawley - Lyme CT
John W. Wong - East Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C12P 1716

US Classification:

435119, 435118, 435120, 435121, 435122, 435877, 435911, 435913, 435933

Abstract:

The present invention relates to processes for the microbial oxidation of 2-methylquinoxaline to 2-quinoxalinecarboxylic acid which comprise contacting 2-methylquinoxaline with a microorganism, or a suitable mutant thereof, and incubating the resulting mixture under conditions sufficient to yield an amount of said 2-quinoxalinecarboxylic acid. The present processes optionally further comprise the isolation and purification of 2-quinoxalinecarboxylic acid.

US Patent:

6451587, Sep 17, 2002

Filed:

Jun 2, 2000

Appl. No.:

09/587032

Inventors:

Michael P. Burns - Mystic CT
John W. Wong - East Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C12P 1712

US Classification:

435280, 435122, 435117, 435118

Abstract:

The present invention relates to microbial processes for carrying out the asymmetric reduction of a ketone to an alcohol, which comprises: contacting the ketone with a microorganism, or an enzyme reduction system capable of accomplishing the subject reduction comprising an enzyme derived from said microorganism and a co-factor for said enzyme, and incubating the resulting mixture under conditions sufficient to yield more of the desired (R)-enantiomer of the corresponding alcohol than the undesired (S)-enantiomer. The chiral (R)-enantiomer can be used in the synthesis of certain -adrenergic receptor agonists.

US Patent:

6589777, Jul 8, 2003

Filed:

Oct 26, 1999

Appl. No.:

09/427424

Inventors:

Brook K. Morse - Colchester CT
Susan J. Truesdell - Warwick RI
John W. Wong - East Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C12P 726

US Classification:

435280, 4352521, 435170, 435171, 43525401

Abstract:

The present invention relates to processes for carrying out the following stereoselective microbial reduction of a racemic tetralone: which comprises: contacting a compound of formula (I) with a microorganism, or an enzyme reduction system capable of accomplishing the subject reduction comprising an enzyme derived from said microorganism and a co-factor for said enzyme, and incubating the resulting mixture under conditions sufficient to yield the (4R) tetralol of formula (II) and to leave substantially unreacted the (4S) tetralone of formula (V) or âchiral tetralone. â The chiral tetralone can be used in the synthesis of sertraline. The subject process further optionally comprises the separation of the (4S) tetralone of formula (V) from the (4R) tetralol of formula (II). The (4R) tetralol can be recycled to produce the compound of formula (I) and the subject process repeated to result in even more of the desired (4S) tetralone of formula (V).

US Patent:

6613550, Sep 2, 2003

Filed:

Feb 28, 2001

Appl. No.:

09/796278

Inventors:

John W. Wong - East Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C12P 1710

US Classification:

435121, 435170, 435171, 435195, 4352521, 4352535, 4352543, 4352561

Abstract:

The present invention is directed to a process for the production of compounds of the formula: from a compound of the formula comprising hydroxylating a compound of the formula I in the presence of an enzyme produced by a microorganism of the genera Cunninghamella species or Aspergillus. Preferred microorganisms are var. elegans and Mixtures of compounds of formulae II and III may also be highly enriched in their composition of compound II by using the enzyme from ATC 8688b.

US Patent:

6689888, Feb 10, 2004

Filed:

Feb 20, 2003

Appl. No.:

10/370793

Inventors:

Robert J. Chambers - Mystic CT
Robert W. Dugger - Stonington CT
Ming Kang - Salem CT
Yong Tao - Salem CT
John W. Wong - East Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D41702

US Classification:

5462697, 5462714, 5462754, 5462711, 5462721

Abstract:

The present invention provides processes useful in the preparation of certain -adrenergic receptor agonists of the structural formula the pharmaceutically acceptable salts thereof, and the hydrates of said pharmaceutically acceptable salts, wherein HET is as described herein. The invention further provides intermediates useful in the preparation of such agonists, and processes useful in the production of such intermediates.

US Patent:

6746856, Jun 8, 2004

Filed:

Aug 8, 2001

Appl. No.:

09/924292

Inventors:

James J. Cawley - Lyme CT
John W. Wong - East Lyme CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

C12P 1700

US Classification:

435117, 435243, 4352541, 4352543, 4352545

Abstract:

The present invention relates to processes for the microbial oxidation of bicyclic heteroaromatic compounds which comprise contacting these compounds with a microorganism, or a suitable mutant thereof, and incubating the resulting mixture under conditions sufficient to yield an amount of their respective carboxylic acids. The present processes optionally further comprise the isolation and purification of the product carboxylic acids.

US Patent:

6919460, Jul 19, 2005

Filed:

Oct 9, 2003

Appl. No.:

10/682762

Inventors:

Robert J. Chambers - Mystic CT, US
Robert W. Dugger - Stonington CT, US
Ming Kang - Salem CT, US
Yong Tao - Salem CT, US
John W. Wong - East Lyme CT, US

Assignee:

Pfizer Inc, - New York NY

International Classification:

C07D213/26
C07D213/46
A61K031/4406

US Classification:

546346, 514355, 546315

Abstract:

The present invention provides processes useful in the preparation of certain β-adrenergic receptor agonists of the structural formula the pharmaceutically acceptable salts thereof, and the hydrates of said pharmaceutically acceptable salts, wherein HET is as described herein. The invention further provides intermediates useful in the preparation of such agonists, and processes useful in the production of such intermediates.

US Patent:

7727749, Jun 1, 2010

Filed:

Apr 1, 2005

Appl. No.:

10/599899

Inventors:

Michael P. Burns - Mystic CT, US
Justin K. Weaver - Clinton IN, US
John Wing Wong - East Lyme CT, US

Assignee:

Pfizer, Inc. - New York NY

International Classification:

C12P 13/04
C12P 13/00
C07C 205/00

US Classification:

435106, 435128, 562553

Abstract:

The present invention is directed to a regio- and stereoselective bioconversion of selected aliphatic dinitriles into corresponding cyanocarboxylic acids. More particularly, the present invention provides methods for the conversion of 2-isobutyl-succinonitrile into (S)-3 cyano-5-methylhexanoic acid, which is a useful intermediate in the synthesis of (S)-3(aminomethyl)-5-methylhexanoic acid (pregabalin). Pregabalin can be used for treating certain cerebral diseases, for example, in the treatment and prevention of seizure disorders, pain, and psychotic disorders.